Literature DB >> 21824820

Prevention of T cell activation by interference of internalized intravenous immunoglobulin (IVIg) with MHC II-dependent native antigen presentation.

Éric Aubin1, Dominic Paquin Proulx, Patrick Trépanier, Réal Lemieux, Renée Bazin.   

Abstract

Activation of self-reactive CD4(+) T cells plays a central role in the initiation and maintenance of autoimmune diseases. We recently reported that intravenous immunoglobulin (IVIg) inhibits the MHC II-restricted CD4(+) T cell activation induced by the presentation of immune complexes. Because native antigens can also play a role in the induction of several autoimmune diseases, we determined whether IVIg could also affect CD4(+) T cell activation following presentation of native antigens by APCs. Here we report that IVIg significantly reduces the activation of CD4(+) T cells by native ovalbumin. The inhibitory effect is FcγR-independent and occurs following internalization of IVIg inside APCs, where it interferes with the intracellular events leading to MHC II-dependent antigen presentation. The effect of IVIg on native antigen presentation could therefore contribute to dampen the autoimmune reaction by reducing CD4(+) T cell activation and the subsequent inflammatory response induced by these cells.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21824820     DOI: 10.1016/j.clim.2011.06.009

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  8 in total

1.  Suppression of blastogenesis and proliferation of activated CD4(+) T cells: intravenous immunoglobulin (IVIg) versus novel anti-human leucocyte antigen (HLA)-E monoclonal antibodies mimicking HLA-I reactivity of IVIg.

Authors:  M H Ravindranath; P I Terasaki; T Pham; V Jucaud; S Kawakita
Journal:  Clin Exp Immunol       Date:  2014-10       Impact factor: 4.330

2.  Immunological evidence and regulatory potential for cell-penetrating antibodies in intravenous immunoglobulin.

Authors:  Aggeliki D Sali; Ioannis Karakasiliotis; Maria Evangelidou; Stratis Avrameas; Peggy Lymberi
Journal:  Clin Transl Immunology       Date:  2015-10-02

Review 3.  Persistent Immune Activation in CVID and the Role of IVIg in Its Suppression.

Authors:  Dominic Paquin-Proulx; Johan K Sandberg
Journal:  Front Immunol       Date:  2014-12-16       Impact factor: 7.561

Review 4.  Fc Gamma Receptors and Their Role in Antigen Uptake, Presentation, and T Cell Activation.

Authors:  Fabian Junker; John Gordon; Omar Qureshi
Journal:  Front Immunol       Date:  2020-07-03       Impact factor: 7.561

Review 5.  Role of HLA-I Structural Variants and the Polyreactive Antibodies They Generate in Immune Homeostasis.

Authors:  Mepur H Ravindranath; Fatiha El Hilali; Carly J Amato-Menker; Hajar El Hilali; Senthamil R Selvan; Edward J Filippone
Journal:  Antibodies (Basel)       Date:  2022-09-08

6.  Tregitopes and impaired antigen presentation: Drivers of the immunomodulatory effects of IVIg?

Authors:  Laetitia Sordé; Sebastian Spindeldreher; Ed Palmer; Anette Karle
Journal:  Immun Inflamm Dis       Date:  2017-05-31

7.  Massive immune response against IVIg interferes with response against other antigens in mice: A new mode of action?

Authors:  Laetitia Sordé; Sebastian Spindeldreher; Ed Palmer; Anette Karle
Journal:  PLoS One       Date:  2017-10-12       Impact factor: 3.240

Review 8.  Immune modulation of i.v. immunoglobulin in women with reproductive failure.

Authors:  Ae R Han; Sung K Lee
Journal:  Reprod Med Biol       Date:  2018-01-24
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.